Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Skyhawk snags $133 million to drug RNA

by Ryan Cross
September 18, 2021 | A version of this story appeared in Volume 99, Issue 34

 

Skyhawk Therapeutics, one of C&EN’s 10 Start-Ups to Watch in 2019, has raised $133 million to further develop small-molecule drugs that modify RNA expression. Skyhawk says it has raised more than $600 million to date and could earn more than $20 billion in milestone payments through collaborations with firms including Bristol Myers Squibb, Merck & Co., and Vertex Pharmaceuticals. The start-up is developing drugs for cancer and for autoimmune, neurodegenerative, neuromuscular, and viral diseases.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.